Ultomiris regulatory submission accepted under FDA Priority Review in the US for adults with generalised myasthenia gravis

Submission based on positive Phase III trial in which Ultomiris significantly improved functional activities as measured by Myasthenia Gravis-Activities of Daily Living Profile  

Related Keywords

Latvia ,Japan ,United States ,Roni ,Kuldigas Novads ,United Kingdom ,Massachusetts ,China ,Italy ,Boston ,Bonifati ,Calabria ,Portugal ,Sweden ,Cambridgeshire ,Ireland ,Cambridge ,America ,Swedish ,Republic Of Ireland ,Marc Dunoyer ,National Organization For Rare Disorders ,Company On Twitter ,Drug Administration ,Alexion Pharmaceuticals Inc ,Nasdaq ,Astrazeneca ,Investor Relations Team ,European Union ,National Institutes Of Neurological Disorders ,York Academy Of Sciences ,Myasthenia Gravis Activities ,Daily Living ,Biologics License Application ,Priority Review ,Prescription Drug User Fee Act ,Rare Disease ,Chief Executive Officer ,North America ,Daily Living Profile ,Myasthenia Gravis Foundation ,America Clinical Classification Class ,Astrazeneca Rare Disease ,Alexion Pharmaceuticals ,Rare Diseases ,For Media ,New York Academy ,Intern Med ,Clinical Characteristics ,Refractory Myasthenia Gravis ,Yale Journal ,North Atlantic ,Neurol Scand ,Northern Portugal ,Eurj Neurol ,Gravis Fact ,National Institutes ,Neurological Disorders ,Accessed October ,National Organization ,Rare Disorders ,Clinical Overview ,Efficacy Study ,Adults With Generalized Myasthenia ,Anatomy ,Autoimmune Diseases ,Disease ,Merger And Acquisition ,Pharmaceuticals ,Stroke ,Atypical Hemolytic Uremic Syndrome ,Branches Of Biology ,Eculizumab ,Myasthenia ,Myasthenia Gravis ,Ocular Myasthenia ,Morgan Systems ,